public health

R&D

A forgotten opioid epidemic, but a mounting problem

Deaths from opioid-related overdoses continue to grow in the US, but public health events of recent times mean that attention has been focused elsewhere.

News

After period of decline, dementia may be on the rise again

While there is widespread fear of an explosion in dementia cases as the global population ages, there has actually been a downward trend in Europe and North America in the

Patients

Growing health inequality in UK prompts call for ‘joined up ...

In the last UK election in 2019, the NHS emerged as a major talking point, as the scale of the country’s support of the service was brought to the fore.

News

Hearing aids could cut cognitive decline in some patients

With so much attention focused on the use of pricey amyloid-busting therapies for A

R&D

JP Morgan 2023 - Astrocyte Pharmaceuticals

pharmaphorum spoke with Astrocyte's Kevin Sheth, William Korinek, and James D. Lechleiter

Views & Analysis

Pharma’s climate change vulnerability and opportunity

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.